Augustin Ferrant
Overview
Explore the profile of Augustin Ferrant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bobillier C, Derclaye I, Ferrant A, Maisin D
EJHaem
. 2024 Feb;
5(1):33-38.
PMID: 38406508
A girl with a sickle cell trait had severe VOCs (vaso-occlusive crises), her father also had a sickle cell trait but mild VOCs, and her mother had no symptoms. Electrophoresis...
2.
Gullaksen S, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, et al.
Haematologica
. 2017 May;
102(8):1361-1367.
PMID: 28522574
Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis, but has so far not been tested in...
3.
Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, et al.
Ann Hematol
. 2016 Mar;
95(6):967-72.
PMID: 26994010
In the context of discussions on the reproducibility of clinical studies, we reanalyzed a prospective randomized study on the role of splenic irradiation as adjunct to the conditioning for hematopoietic...
4.
Vekemans M, Lambert C, Ferrant A, Saussoy P, Havelange V, Debieve F, et al.
Blood Coagul Fibrinolysis
. 2015 Feb;
26(4):464-6.
PMID: 25688464
Pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) is associated with increased maternal and fetal complications, to such an extent that PNH has for long been considered a relative contraindication...
5.
Vekemans M, Michaux L, Saussoy P, Van den Neste E, Theate I, Ferrant A
Ann Hematol
. 2015 Jan;
94(6):1077-8.
PMID: 25634495
No abstract available.
6.
Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, et al.
Ann Hematol
. 2014 Aug;
94(1):23-34.
PMID: 25096636
High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related...
7.
Vekemans M, Michaux L, Van den Neste E, Ferrant A
Br J Haematol
. 2014 Apr;
166(4):616-8.
PMID: 24697308
No abstract available.
8.
Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, et al.
Leuk Res
. 2014 Mar;
38(5):557-63.
PMID: 24661630
Background: Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could...
9.
Ades L, Chevret S, Raffoux E, Guerci-Bresler A, Pigneux A, Vey N, et al.
Am J Hematol
. 2013 Apr;
88(7):556-9.
PMID: 23564205
All-trans retinoic acid (ATRA) combined to anthracycline-based chemotherapy is the reference treatment of acute promyelocytic leukemia (APL). Whereas, in high-risk patients, cytarabine (AraC) is often considered useful in combination with...
10.
Vellenga E, van Putten W, Ossenkoppele G, Verdonck L, Theobald M, Cornelissen J, et al.
Blood
. 2011 Sep;
118(23):6037-42.
PMID: 21951683
We report the results of a prospective, randomized phase 3 trial evaluating autologous peripheral blood stem cell transplantation (ASCT) versus intensive consolidation chemotherapy in newly diagnosed AML patients in complete...